Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TPX2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TPX2 Recombinant Protein (Full-Length & Truncated Domains) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for PPI assays. |
View TPX2 Products |
| Gene Delivery | TPX2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View TPX2 Products |
| Benchmark Ab | Anti-TPX2 Recombinant Antibody Recombinant positive control for immunofluorescence and Western blot validation. |
View TPX2 Products |
| Validator | TPX2 siRNA Set For knockdown verification and specificity controls in phenotypic assays. |
View TPX2 Products |
| Related Target A | AURKA (Aurora Kinase A) Direct binding partner of TPX2; TPX2 binding activates AURKA kinase activity during mitosis. |
View AURKA Products |
| Related Target B | KIF11 (Eg5) Kinesin family member cooperating with TPX2 in spindle pole organization. |
View KIF11 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Disrupting TPX2-AURKA Protein-Protein Interaction (PPI) | Highly stable, sequence-verified recombinant TPX2 N-terminal domain (AURKA-binding region) and full-length AURKA. |
| Off-target Tubulin-binding Screening | High-purity homologous spindle-associated protein panels strictly verified by mass spectrometry. |
| Lack of Controls | Clinical-grade benchmark antibodies and validated positive controls included in the development package. |
| False Positives in Small Molecule Screening | Sequence-verified siRNA sets included for target knockdown and specificity validation in cell-based assays. |
Live TPX2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TPX2 therapeutics is intensifying, with major players shifting focus from traditional microtubule stabilizers to targeted protein-protein interaction (PPI) inhibitors and targeted protein degraders (PROTACs). As first-generation mitotic inhibitors reach the clinic, the next wave of R&D is targeting the TPX2-AURKA signaling axis to overcome resistance in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Consortia, Biotech Startups | Triple-Negative Breast Cancer, NSCLC | Disruption assays (Need high-purity TPX2/AURKA recombinant proteins) |
| PROTACs / Degraders | Oncology-focused Biopharma | Ovarian Cancer, Hematological Malignancies | Degradation kinetics (Need TPX2 Lentivirus for stable cell lines) |
| RNA Therapeutics (siRNA/ASO) | RNAi Specialists | Refractory Solid Tumors | Knockdown efficiency validation (Need validated siRNA sets) |